Pharmacologic Ascorbate Reduces Radiation-Induced Normal Tissue Toxicity and Enhances Tumor Radiosensitization in Pancreatic Cancer

• Published in: Cancer research (Chicago, Ill.) Vol. 78; no. 24; pp. 6838 - 6851
• Main Authors: Alexander, Matthew S., Wilkes, Justin G., Schroeder, Samuel R., Buettner, Garry R., Wagner, Brett A., Du, Juan, Gibson-Corley, Katherine, O’Leary, Brianne R., Spitz, Douglas R., Buatti, John M., Berg, Daniel J., Bodeker, Kellie L., Vollstedt, Sandy, Brown, Heather A., Allen, Bryan G., Cullen, Joseph J.
• Format: Journal Article
• Language: English
• Published: United States 15.12.2018
• Subjects: Aged; Aged, 80 and over; Animals; Ascorbic Acid - pharmacology; Cell Line, Tumor; Cell Proliferation; Cell Survival; Collagen - metabolism; Deoxycytidine - administration & dosage; Deoxycytidine - analogs & derivatives; Disease-Free Survival; DNA Damage; Female; Glutathione - metabolism; Humans; Male; Mice; Mice, Nude; Middle Aged; Oxidative Stress; Pancreatic Neoplasms - drug therapy; Pancreatic Neoplasms - radiotherapy; Radiation Tolerance; Radiotherapy; Recombinant Proteins - metabolism; Treatment Outcome

: Chemoradiation therapy is the mainstay for treatment of locally advanced, borderline resectable pancreatic cancer. Pharmacologic ascorbate (P-AscH , i.e., intravenous infusions of ascorbic acid, vitamin C), but not oral ascorbate, produces high plasma concentrations capable of selective cytotoxici...